Get the Stockscreener App
1.23
1.67%
0.03
Climb Bio Inc stock is traded at $1.23, with a volume of 26,542.
It is up +1.67% in the last 24 hours and down -5.43% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
See More
Previous Close:
$1.20
Open:
$1.23
24h Volume:
26,542
Relative Volume:
0.17
Market Cap:
$92.58M
Revenue:
-
Net Income/Loss:
$-64.20M
P/E Ratio:
-0.5721
EPS:
-2.15
Net Cash Flow:
$57,000
1W Performance:
-3.17%
1M Performance:
-5.43%
6M Performance:
-39.75%
1Y Performance:
+0.00%
1-Day Range:
$1.20
$1.2899
1-Week Range:
$1.20
$1.31
52-Week Range:
$1.05
$5.47
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
1.22 | 92.58M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.78 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
514.38 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.97 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.27 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
257.25 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-25 | Initiated | Oppenheimer | Outperform |
| May-22-25 | Initiated | BTIG Research | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
Climb Bio Inc Stock (CLYM) Latest News
Bristol Myers Squibb (BMY) Loses Key Executive to Climb Bio | BM - GuruFocus
Climb Bio Appoints Cindy Driscoll as Finance VP - TipRanks
Climb Bio appoints new chief medical officer and finance executive - Investing.com
Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer - Bluefield Daily Telegraph
Bristol Myers Squibb Immunology Leader Joins Climb Bio to Advance Breakthrough Autoimmune Programs - Stock Titan
UroGen continues to climb after bladder cancer drug approval - Seeking Alpha
Honda CR-V e:FCEV to Challenge Pikes Peak Hill Climb as First-Ever Hydrogen Powered Race Entry - Honda Newsroom
Metsera shares climb on early data for amylin-targeting obesity shot - BioPharma Dive
Head to Head Contrast: Monopar Therapeutics (NASDAQ:MNPR) vs. Climb Bio (NASDAQ:CLYM) - Defense World
Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Sold by Two Sigma Advisers LP - Defense World
Climb Bio (NASDAQ:CLYM) Coverage Initiated at Oppenheimer - Defense World
Biotech Finishes Week Strong On Bullish Analyst Outlook - MSN
Public Employees Retirement System of Ohio Acquires 1,768 Shares of Nu Skin Enterprises, Inc. (NYSE:NUS) - Defense World
Oppenheimer Initiates Coverage of Climb Bio (CLYM) with Outperform Recommendation - Nasdaq
Circle Internet Group Stock Keeps Climbing After Big Debut - Investopedia
Oppenheimer initiates coverage on Climb Bio stock with outperform rating - Investing.com
Krill Oil Market Expected to Climb to US$ 333.2 Mn by 2032Persistence Market Research - openPR.com
Oppenheimer initiates coverage on Climb Bio stock with outperform rating By Investing.com - Investing.com UK
Oppenheimer Initiates Climb Bio at Outperform With $10 Price Target - marketscreener.com
Climb Bio Elects New Board Members at Annual Meeting - TipRanks
Stocks Climb on Hopes of Easing US-China Trade Tensions - The Globe and Mail
BNP Paribas Financial Markets Has $69,000 Stock Holdings in Climb Global Solutions, Inc. (NASDAQ:CLMB) - Defense World
This stealth AI supplier just leapfrogged 206 companies on the Fortune 500 - Fortune
NIO EV Deliveries Surge 34.7% in 2025, May Numbers Show Strong Multi-Brand Growth - Stock Titan
Nuveen Asset Management LLC Acquires 53,376 Shares of Innodata Inc. (NASDAQ:INOD) - Defense World
Climb Bio (NASDAQ:CLYM) Upgraded at BTIG Research - Defense World
Are Wall Street Analysts Predicting Agilent Technologies Stock Will Climb or Sink? - MSN
Climb Bio Appoints Interim CFO Amid Leadership Change - TipRanks
BTIG sets Climb Bio stock Buy rating, $7 target By Investing.com - Investing.com Nigeria
BTIG sets Climb Bio stock Buy rating, $7 target - Investing.com
BioArctic shares climb on Q1 profit beat, boosted by Bristol payment - Investing.com Canada
Strong week for Access Bio (KOSDAQ:950130) shareholders doesn't alleviate pain of three-year loss - simplywall.st
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
What is Leerink Partnrs’ Estimate for Climb Bio Q2 Earnings? - Defense World
Climb Bio Awards $152K Stock Package to New Executive: Inside the Biotech's Latest Talent Investment - Stock Titan
Mercer Global Advisors Inc. ADV Sells 340 Shares of Atlantic Union Bankshares Co. (NASDAQ:AUB) - Defense World
Climb Bio Reports Increased Losses Amid Ongoing Development - TipRanks
Amazon.com, Inc. (NASDAQ:AMZN) Shares Sold by Capital Research Global Investors - Defense World
Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Tilray Brands Announces the Launch of XMG Atomic Sours: New THC Beverages and Edibles - The Manila Times
Climb Bio reports Q1 EPS (31c) vs (6c) last year - TipRanks
Climb Bio, Inc. SEC 10-Q Report - TradingView
Climb Bio (CLYM) Expected to Announce Earnings on Wednesday - Defense World
Life sciences firms climb after US and China agree to cut tariffs - TradingView
Sector Update: Health Care Stocks Climb Monday Afternoon - marketscreener.com
S&P 500 Gains & Losses Today: Index Pulls Back Early Climb Amid Anticipation of Trade Talks - Investopedia
Exec Edge Launches Research Coverage with Initiation Notes on FL - GuruFocus
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB - Quantisnow
Market Update: Climb Bio Inc (CLYM) Sees Positive Movement, Closing at 1.21 - DWinneX
Stock Index Futures Climb on U.S.-China Trade Talk Optimism, Fed Rate Decision in Focus - The Globe and Mail
Astaxanthin Market Size to Climb USD 6.86 Billion by 2034 - Precedence Research
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Climb Bio Inc Stock (CLYM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pimblett Emily | CHIEF ACCOUNTING OFFICER |
Dec 19 '24 |
Sale |
2.02 |
1,235 |
2,495 |
11,329 |
| Pimblett Emily | CHIEF ACCOUNTING OFFICER |
Sep 20 '24 |
Sale |
8.18 |
1,191 |
9,741 |
7,564 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 22 '24 |
Sale |
8.03 |
69,005 |
554,170 |
31,317 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 19 '24 |
Sale |
7.21 |
60,201 |
434,325 |
100,322 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 18 '24 |
Sale |
6.93 |
38,576 |
267,332 |
160,523 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 17 '24 |
Sale |
6.91 |
3,207 |
22,160 |
199,099 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 16 '24 |
Sale |
7.13 |
50,000 |
356,500 |
202,306 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 12 '24 |
Sale |
7.07 |
50,000 |
353,500 |
294,683 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 15 '24 |
Sale |
7.01 |
42,377 |
297,063 |
252,306 |
| Morisset Valerie | EVP, R&D AND CSO |
Jul 11 '24 |
Sale |
7.11 |
50,000 |
355,500 |
344,683 |
1.59%
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):